Navigation Links
Use Of Cryoablation For Treatment Of Breast Cancer Shows Promising Results
Date:5/7/2013

CHICAGO, May 7, 2013 /PRNewswire/ -- Dr. Eisuke Fukuma has treated 58 breast cancer patients with cryoablation over the last 6 years under a research protocol at Kameda Medical Center in Japan.  As of today, none of the patients have had a tumor reoccur or distant metastases. By this non-surgical treatment, Dr. Fukuma's patients avoid the risks and potential cosmetic impact of major breast cancer surgery.  The fact that none have had recurrences, suggests that, with further study, Cryoablation may offer significant, minimally-invasive breast health options.

(Photo: http://photos.prnewswire.com/prnh/20130507/CL09547)

Cryoablation is the technique of using extreme cold to destroy tissue.  It has been used for years in medical applications like dermatology, kidney, prostate and liver to treat both cancerous and non-cancerous tumors.

Eisuke Fukuma , MD, PhD, is Chairman of Breast Center at Kameda Medical Center in Kamogawa  City, Chiba, Japan.  Since 2006, his team has been developing cryoablation under image-guidance as a nonsurgical treatment for small breast cancer.

Dr. Fukuma's most recent 20 patients added to the clinical trial were treated using the IceSense3 Cryoablation system from IceCure Medical. While mainstream cancer treatment still requires significant research, the IceSense3 system is widely available in the US for the treatment of benign breast disease.  The procedure usually takes about 10-15 minutes; with no pain and virtually no scar (no sutures are required). As with a needle biopsy, many women can return to work or their normal activity quickly.

Dr. Fukuma previewed his next steps in research, which include expanding his research for larger tumors using the IceSense3, to a packed room of physicians and researchers at the 2013 conference of the American Society of Breast Surgeons (ASBrS).  To determine if nonsurgical cryoablation is an acceptable treatment for patients with small breast cancer, "we have to study a larger number of patients for a longer time period," remarks Dr. Fukuma.

Because of its procedural, clinical, and cosmetic results, Cryoablation garnered high level of attention at the conference.  Author of several pivotal studies on Cryoablation of benign tumors, Dr. Cary Kaufman also spoke about its use in breast cancer, adding that it has potential immunological benefits.

"We are extremely excited with the results presented by Dr. Fukuma," stated Hezi Himelfarb , President and CEO of IceCure Medical. "IceSense3 cryoablation system will continue to have major role in Dr. Fukuma's study towards providing less invasive and better cosmetic options for patients."

The IceSense3™ Cryoablation System was designed for efficient and effective treatment of breast tumors. The system has 510k FDA approval for benign and malignant breast disease.

About IceCure Medical

IceCure Medical, Inc.is a medical device company focused on developing and marketing minimally invasive, office-based cryoablation treatment solutions for women's health. The proprietary IceSense3™ Cryoablation System offers a comfortable, ultrasound-guided procedure to treat breast tumors. To learn more about IceCure and Cryoablation for Breast Disease, please find us on the web at www.IceCure-Medical.com.  To learn about patient advocacy efforts follow us @CoverCryo on Twitter and BreastHealthOptions on Facebook.

For more information, contact
Will Irby
IceCure Medical, Inc.
(901) 237-4630
wirby@icecure-medical.com


'/>"/>
SOURCE IceCure Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Ablation Technologies Market (2011-2016) - By Application and Devices in Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Electrical, Light/Laser and Hydromechanical - Global Trends & Competitive Analysis
2. Ablation Devices Market to 2016 - (Radiofrequency, Cryoablation, Microwave, Ultrasound, Hydrothermal, Radiation, Cardiac, Cancer and Gynecology) - Global Market Forecast and Trends Analysis by Technology, Devices & Applications
3. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
4. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
5. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
6. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
7. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
8. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
9. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
10. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
11. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 FinancialBuzz.com News Commentary  ... According to ... cannabis market research, the legal cannabis market is projected to ... despite conflicting signals from the current presidential administration. The report ... two biggest drivers of growth in this industry are the ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... and Diagnostics, 2017 - 2035" report to their offering. ... The Deep Learning: Drug ... future outlook of the growing market of deep learning solutions within ... learning algorithms have emerged as a novel solution to generate relevant ...
(Date:3/24/2017)... YORK , March 24, 2017 ... and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic ... Heart Inc. (NASDAQ: SSH ). These companies are ... its prior gains on Thursday, March 23 rd , 2017, ... afternoon, while shares of health care companies in the S&P ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 to ... responsible for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To combat ... which proposes a tax on prescription opioids to fund drug rehabilitation and prevention ...
(Date:3/25/2017)... PA (PRWEB) , ... March 25, 2017 , ... Getting ... as a public relations partner. , All through the year, Garden Media aims ... press releases, working with key influencers and pitching client’s key messages to ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Infection,” which will spark a conversation on the current obstacles facing infection prevention ... of completely preventable deaths caused by these infections. , The print component ...
(Date:3/24/2017)... ... 2017 , ... According to a new study by NCPA Senior Fellow John ... the rules Congress has directed the CBO to follow. The CBO itself previously recognized ... Yet, it estimates a reduction in employer-based coverage due to the GOP reform, which ...
(Date:3/24/2017)... Sedona, Arizona (PRWEB) , ... March 24, 2017 ... ... Shamangelic Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Jorge Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during ...
Breaking Medicine News(10 mins):